Attracting significant investment from Maximon, the health data startup is aiming for multi-million dollar turnover by end of year.
Swiss-based longevity startup Biolytica announced today that it has successfully secured funding totalling CHF 5.25m (US$5.8m) from the Maximon Longevity Co-Investment Fund.
Biolytica’s focus is its Biolytica NEXUS health data platform, a revolutionary AI-driven analytics platform that aggregates, visualizes and analyzes a whole raft of data, including genomics, blood, microbiome and epigenetic biomarkers, wearable devices, lifestyle data and more.
Biolytica uses the data to generate solutions for healthcare professionals, including those based at preventive medicine institutions, longevity centers and personalized wellness clinics. The data can also be used by insurance companies and others to create science-based, hyper-personalized client health journeys.
Longevity.Technology: Biolytica claims its NEXUS platform is the first platform to truly integrate all aspects of health and lifestyle, allowing it to use data from the full spectrum of human biology. With conceptual origins going back to 2016, Biolytica incorporated in October 2021 and exited stealth last year. It launched its data-focused, silo-busting NEXUS platform to healthcare institutions in early 2023; already generating a 6-figure turnover, the company expects to hit mid-7 figures by the end of this year.
“We are thrilled to have Maximon’s support in our mission to revolutionize how we think about health and prevention in particular,” says Dr Rob Konrad Maciejweski, CEO and Founder of Biolytica. “With the investment from Maximon, we aim to establish ourselves as the leading data platform for preventive healthcare and longevity, and continue to drive innovation in personalized health and wellness.”
Biolytica currently has a team of more than 40 global experts in health data, analytics, software development, bioinformatics and AI, as well as a team of clinical experts from around the globe – and support from 10 scientific and medical advisors.
In addition to their B2B platform services, they also offer B2C concierge health optimization and longevity programs, provided by their internal team of longevity experts and backed by their Biolytica NEXUS platform. These “AIME” programs offer personalized guidance and support for clients seeking to optimize their health and extend their lifespan leveraging a data- and science-driven approach.
Maximon’s backing underscores the growing interest in and demand for longevity solutions backed by solid scientific research. As people around the world seek ways to extend their healthy lifespan, and the move from “sick-care” to “health-care” trends, Biolytica is poised to become a leader in this rapidly evolving field.
“The team at Biolytica is at the forefront of hyper-personalized health, data analytics and lifespan extension,” says Joerg Rieker, Founding Partner at Maximon and Board Member of Biolytica.
“We are confident that their unique approach to science-based, data-driven and AI supported healthcare will have a transformative impact not only on the longevity industry, but on healthcare and prevention in general.”
Biolytica plans to use the new funding to expand its research and development efforts, scale its services to reach a wider client base and collaborate with the leading experts and clinics in the field of personalized and preventive healthcare.
